2 recruiting, 1 completed. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Completed 1 |
| Phase 2 | 2 | Recruiting 2 |
Follow Granuloma, Plasma Cell: new trials by email Literature Review of Granuloma, Plasma Cell trials Research Report on Granuloma, Plasma Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors Brigatinib - Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor | Phase 1 / Phase 2 | Recruiting | Princess Maxima Center for Pediatric Oncology | 65 | 2022-08-18 | 2025-12-05 |
| A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations Oral repotrectinib (TPX-0005) - Locally Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Turning Point Therapeutics, Inc. | 75 | 2020-03-12 | 2026-09-25 |
| Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) Ceritinib - ALK-activated Tumors | Phase 1 | Completed | Novartis Pharmaceuticals | 83 | 2013-08-28 | 2020-06-09 |
Lymphoma, Large-Cell, Anaplastic (3) · Glioblastoma (1) · Glioma (1) · Lymphoma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Neuroblastoma (1) · Rhabdomyosarcoma (1) · Sarcoma (1) · Solitary Fibrous Tumors (1)
Granuloma (3) · Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoma, Non-Hodgkin (3) · Lymphoma, T-Cell (3) · Lymphoproliferative Disorders (3) · Neoplasms by Histologic Type (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Lymphoma (2) · Neoplasms (2) · Neoplasms, Connective and Soft Tissue (2) · Neoplasms, Germ Cell and Embryonal (2)
Capsules (1) · Suspensions (1) · brigatinib (1) · ceritinib (1) · repotrectinib (1)
Novartis Pharmaceuticals (1) · Princess Maxima Center for Pediatric Oncology (1) · Turning Point Therapeutics, Inc. (1)
France (3) · Australia (2) · Canada (2) · Italy (2) · Netherlands (2) · South Korea (2) · Spain (2) · United Kingdom (2) · United States (2) · Denmark (1) · Germany (1) · Singapore (1) · Taiwan (1)
PMID 30697903, PMID 34780709, PMID 34814185
2023 (1)